ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,780.83
0.08%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Avidity Biosciences Inc (RNA)

  7. Avidity Biosciences Inc (RNA) News

Avidity Biosciences (RNA)

Avidity Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RNA
DateTimeSourceHeadlineSymbolCompany
29/05/202421:05PR Newswire (US)Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research CongressNASDAQ:RNAAvidity Biosciences Inc
21/05/202421:05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
16/05/202423:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
16/05/202423:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
15/05/202414:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAAvidity Biosciences Inc
15/05/202414:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
15/05/202414:00PR Newswire (US)Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of DirectorsNASDAQ:RNAAvidity Biosciences Inc
09/05/202421:22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RNAAvidity Biosciences Inc
09/05/202421:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNAAvidity Biosciences Inc
09/05/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
09/05/202421:05PR Newswire (US)Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
08/05/202421:05PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferenceNASDAQ:RNAAvidity Biosciences Inc
08/05/202411:00PR Newswire (US)Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1NASDAQ:RNAAvidity Biosciences Inc
08/05/202402:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
22/04/202421:05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
27/03/202413:00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:RNAAvidity Biosciences Inc
21/03/202420:05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
08/03/202421:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNAAvidity Biosciences Inc
05/03/202421:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
04/03/202412:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
04/03/202412:00PR Newswire (US)Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ TrialNASDAQ:RNAAvidity Biosciences Inc
01/03/202421:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNAAvidity Biosciences Inc
29/02/202421:19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RNAAvidity Biosciences Inc
29/02/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
29/02/202417:00PR Newswire (US)Avidity Biosciences Honors Rare Disease Day®NASDAQ:RNAAvidity Biosciences Inc
29/02/202412:00PR Newswire (US)Avidity Biosciences Announces Oversubscribed $400 Million Private PlacementNASDAQ:RNAAvidity Biosciences Inc
28/02/202422:32Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RNAAvidity Biosciences Inc
28/02/202421:17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RNAAvidity Biosciences Inc
28/02/202421:05PR Newswire (US)Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
27/02/202414:00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:RNAAvidity Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:RNA

Your Recent History

COIN
BURNEUR
Blockburn
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved